Trump's Psychedelic Medicine Executive Order: What It Means for Patients and Investors

Send us Fan MailWater Tower Research's healthcare equity analyst Robert Sassoon breaks down President Trump's executive order on therapeutic psychedelics, examining the five key mechanisms it puts in place — from accelerated FDA review vouchers and right-to-try expansion to federal funding and ibogaine pathway clearance. Sassoon explains what the order gets right, where it falls short (namely on reimbursement and rescheduling), and which companies — including Compass Pathways, Dephinium Therapeutics, and Helus Pharma — stand to benefit most as the sector gains its first clear federal endorsement as a legitimate therapeutic class.